CLINUVEL: update on Level II ADR upgrade, Nasdaq uplist 2026 Announcements . Clinical . News 28.04.2026
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study 2026 Announcements . Clinical . News 24.04.2026
CLINUVEL reports highlights from AAD 2026 2026 Announcements . Clinical . Corporate . News 02.04.2026
Controlled-release injectable peptide platform evaluated in preclinical study 2026 Announcements . Clinical . News 12.01.2026
SCENESSE® efficacy in vitiligo: new cases presented at RDTC Conference 2026 Announcements . Clinical . News 08.01.2026
Health Canada requests additional time for review of SCENESSE® in EPP 2025 Announcements . Clinical . News . Regulatory 16.10.2025
CLINUVEL to advance novel pharmaceutical formulations in preclinical program 2025 Announcements . Clinical . News 29.09.2025
EMA approves year-round SCENESSE® treatment 2025 Announcements . Clinical . News . Regulatory 23.09.2025
SCENESSE® efficacy in vitiligo: new cases presented to EADV 2025 Announcements . Clinical . News 19.09.2025
Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo 2025 Announcements . Clinical . News 18.06.2025